Head-to-head · free

Novartis AG vs Insulet Corp.

NVS vs PODD — return on capital, cash generation, margins and balance sheet side by side.

NVS

4 / 5

measures where NVS leads

PODD

1 / 5

measures where PODD leads

A simple count of which company scores better on each measure — not a recommendation to buy or sell.

MeasureNVSPODD · FY2025
Revenue—$2.7B
Net income—$247.1M
Revenue growth (yearly, multi-year)—25.3%
Free cash flow—$377.7M
Free cash flow margin—13.9%
Net cash / (debt)——
ROIC18.6%13.6%
Return on equity31.0%18.1%
Gross margin75.8%71.6%
Operating margin31.1%17.5%
Net debt / EBITDA0.96x0.41x

Figures are as reported by each company; latest fiscal year shown.

Where Novartis AG's cash went

Not reported yet.

Full NVS profile →

Where Insulet Corp.'s cash went (FY2025)

Capital spending
$191.6M
Buybacks
—
Dividends
—
Acquisitions
—
Net debt issued / (repaid)
—
Full PODD profile →

Ask which business is stronger

"Which one reinvests at higher returns?" "Who carries more risk in its filings?" Get answers drawn straight from both companies' filings.

Compare them free

More comparisons